Rapid Influenza A Testing for Novel H1N1:

Point-of-Care Performance

Log in or subscribe to view full content.
Article is also available for purchase the article in one of the available formats.
Claudia Fernandez, MD; Mary Cataletto, MD; Paul Lee, MD; Martin Feuerman, MD; and Leonard Krilov, MD

Table of Contents

Postgraduate Medicine:

Volume 122 No. 1

Category:

Clinical Focus

Purchase this article in one of the formats specified below:

DOI: 10.3810/pgm.2010.01.2096
Abstract: Objectives: The 2009 outbreak of novel influenza A H1N1 reached a pandemic status on June 11, 2009. Early detection is a key factor for management and infection-control practices. Recent studies have suggested a difference in performance of rapid influenza kits for influenza A H1N1. Our goal was to evaluate the performance of the QuickVue® influenza A+B test (Quidel Corp., San Diego, CA) in an emergency department setting and determine the most current epidemiologic trends in our community. Methods: Results from 1137 samples for influenza A collected between April 8, 2009 and June 30, 2009 were retrospectively reviewed. Results of QuickVue® influenza A+B test were compared with R-Mix viral culture and DFA results. Age distribution and hospitalization rates by age group were analyzed to further delineate the epidemiology of influenza A in a suburban hospital. Results: The sensitivity of the rapid test was 77%, the specificity was 85%, the positive predictive value was 74%, and the negative predictive value was 87%. We found a similar age distribution for positive influenza tests and admissions when compared with the national Centers for Disease Control and Prevention data. Conclusions: The QuickVue® influenza A+B test is a sensitive assay for the novel H1N1 strain of influenza. In our hospital, the group with highest risk of hospital admission was patients aged < 25 years.

Keywords: H1N1 , influenza , vaccination , swine flu